Author Index Vol. 80, 2008
Jong Yoon Bahk, Steven K. Huang(University of California, Berkeley), Hae‐Young Lee(Seoul National University Hospital), Miguel Srougi(D’Or Institute for Research and Education), Hitendra Patel(UC San Diego Health System), Axel S. Merseburger(Universitäres Kinderwunschzentrum Lübeck), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Alessandro Sciarra(Policlinico Umberto I), Valeria Panebianco(Sapienza University of Rome), Eva Koch, Alfarone Andrea, Hui-Ju Tsai(Kaohsiung Medical University), Burcu Esen Akkaş, Ulderico Parente, Stefan Hinz(Charité - Universitätsmedizin Berlin), Moon Seok Park, S. Mičić(Polyclinic General Hospital), Siân Allen, Perikles Simon(Johannes Gutenberg University Mainz), M.T. Kitapci, Frank Christoph(Charité - Universitätsmedizin Berlin), Chi‐Jung Chung(China Medical University), Martin Schostak(Aturo), Miroslav Stojadinović, Stephan Kruck(University Children's Hospital Tübingen), Roberto Passariello(Ospedale di Cattinara), Magnus Von Heland(Policlinico Umberto I), Arnulf Stenzl(University of Tübingen), Bong Chul Chung, Timo Joensuu(University of Helsinki), Jeong Hee Lee(Suzhou Electronic Products Inspection), Ursula Kuehs, D. Milovanović, İlker Şen, Myeong Ok Kim(Gyeongsang National University), Markus A. Kuczyk(Medizinische Hochschule Hannover), Jason St John, Seung Ki Min, Cenk Acar, F. Di Silverio(Sapienza University of Rome), Kurt Miller(Charité - Universitätsmedizin Berlin), Joerg Hennenlotter, Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Steffen Weikert(St. Hedwig-Krankenhaus), Tim O’Brien, İlker Akyol, Mo-Hsiung Yang, Selim Sözen, Oliver W. Hakenberg, Matthew J. Perry
Cited by 0
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
|JNCI Journal of the National Cancer Institute|2005|830